|Page (1) of 1 - 07/19/18||email article||print page|
(July 19, 2018)
NEW YORK, July 19, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, rang the Nasdaq Stock Market Opening Bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
Rubius Therapeutics is pioneering a new era of medicines called Red Cell Therapeutics™. The company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. The company plans to file its first Investigational New Drug application for RTX-134 in phenylketonuria, a rare disease that affects 13,000 people in the U.S., during the first quarter of 2019, with additional INDs in 2019, 2020 and beyond.
“Rubius Therapeutics is advancing the development of Red Cell Therapeutics with the potential to treat patients with rare diseases, cancer and autoimmune diseases,” said Pablo J. Cagnoni, M.D., Chief Executive Officer. “We are honored to join the Nasdaq family as we advance our vision of providing life-changing and life-saving benefits to patients.”
“Rubius Therapeutics has been pioneering the creation of cellular therapies for patients,” said Nelson Griggs, President of the Nasdaq Stock Exchange. “We are excited to welcome Rubius and its experienced leadership team to join Nasdaq alongside with the world’s leading biotechnology and pharmaceutical companies as they continue their journey as a public company.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
|Media Relations Contact: |
- NDAQG -
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4f510755-220f-4a53-b928-aa04be5f4dc2
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter